RGH-706 as a Potential Therapeutic for PWS

Study Purpose

KITE PWS is a Phase 2 study to investigate the effects of RGH-706 in people with Prader-Willi Syndrome.  This study is seeking people aged 17 years and older with Prader-Willi syndrome for participation and will evaluate an experimental oral drug that may help to reduce appetite. The study lasts 5-6 months and requires about 8 study visits.

The purpose of this study is to learn more about an experimental drug called RGH-706. RGH-706 is an experimental oral drug that blocks melanin-concentrating hormone (MCH), which is a key part of the brain’s food-seeking mechanism. When this hormone attaches to specific receptors in the brain (i.e., proteins on the outside of brain cells), it increases the desire to eat. RGH-706 may help to block this hormone and reduce appetite.

The study drug, clinic visits, and study-related procedures are provided at no cost. Participants and caregivers may also receive reimbursement for travel and meals. 


Recruitment Criteria

Study Type: Interventional
Eligible Ages: 17 years and older
Other Criteria: 

To be in the study, participants must meet the following basic criteria:

  • Are at least 17 years of age
  • Have a diagnosis of PWS
  • Have a body weight of greater than 40 kg (88 lbs.) and less than 200 kg (450 lbs.)
  • Have had a stable body weight for the past 3 months
  • Have at least 1 consistent and reliable primary caregiver who can evaluate changes in the participant’s hyperphagia symptoms, mood, health, and behavior throughout the study
  • Do not have uncontrolled diabetes or diabetes that requires insulin

Medical history and other criteria will also be reviewed to determine eligibility. See the trial listing at clinicaltrials.gov for a full list of inclusion and exclusion criteria. 

Trial Details

ClinicalTrials.Gov Id: NCT05322096
Phase: 2
Duration: 5-6 months with 8 study visits
Lead Sponsor: Gedeon Richter
Countries: United States, Czechia, France, Italy, Spain


This study will be available at the following sites:  

Multiple sites are available in the United States, Czechia, France, Italy, Spain

Visit ClinicalTrials.Gov the most current list of sites.                                                                                     


Contact: Medical Information Scientific Service
Phone: +36 1 505 7032
Email: medinfo@richter.hu



New Call-to-action